Yifeng Pharmary(SH:603939) Shang Hai Zheng Quan Bao·2025-04-22 21:08Core Viewpoint - The company is utilizing idle raised funds for entrusted financial management to enhance fund efficiency and increase returns while ensuring that the original purpose of the raised funds remains unchanged [3][13]. Group 1: Entrusted Financial Management Details - The amount for entrusted financial management is 212 million yuan [4]. - The source of the funds is idle raised funds [5]. - The company has received approval from the China Securities Regulatory Commission for issuing convertible bonds totaling 1.797 billion yuan, with a net amount of approximately 1.780 billion yuan after deducting issuance costs [6]. Group 2: Approval and Procedures - The board of directors approved the proposal for using idle raised funds for entrusted financial management during the 15th meeting of the 5th board on April 15, 2025, allowing a maximum of 300 million yuan for this purpose [8]. - The investment products will be selected based on high safety and liquidity, with a validity period of 12 months for the approved amount [8]. Group 3: Risk Management and Control Measures - The company will conduct strict evaluations of investment products, focusing on low-risk financial products, while acknowledging potential market volatility risks [9][10]. - Measures include maintaining an investment ledger, regular audits by the audit department, and oversight by independent directors and supervisors [10][11]. Group 4: Impact on the Company - The investment in short-term financial products will not affect the normal operation of the company's main business or its daily cash flow needs [13]. - This strategy aims to generate additional investment returns, enhancing the company's performance and providing better returns for shareholders [13].